Although the potential toxicity of IL-2 treatment in patients with type 1 diabetes has been reported, we note very high doses of Proleukin were used which were accompanied by a large induction of NK cells and eosinophils [51]. Here, IL2 is linked to type 1 diabetes mellitus.